These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2397145)

  • 21. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-specific activation of prodrugs: is there a role for nuclear medicine?
    Antunes IF; Haisma HJ; de Vries EF
    Nucl Med Commun; 2008 Oct; 29(10):845-6. PubMed ID: 18769302
    [No Abstract]   [Full Text] [Related]  

  • 23. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
    Bagshawe KD
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1421-31. PubMed ID: 17069527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
    Heinis C; Alessi P; Neri D
    Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prodrug activation enzymes in cancer gene therapy.
    Aghi M; Hochberg F; Breakefield XO
    J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteases as activators for cytotoxic prodrugs in antitumor therapy.
    Weidle UH; Tiefenthaler G; Georges G
    Cancer Genomics Proteomics; 2014; 11(2):67-79. PubMed ID: 24709544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enantio- and diastereoselective synthesis of duocarmycine-based prodrugs for a selective treatment of cancer by epoxide opening.
    Tietze LF; Schuster HJ; Hampel SM; Rühl S; Pfoh R
    Chemistry; 2008; 14(3):895-901. PubMed ID: 18033701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of cytotoxic agents by targeted enzymes.
    Senter PD; Wallace PM; Svensson HP; Vrudhula VM; Kerr DE; Hellström I; Hellström KE
    Bioconjug Chem; 1993; 4(1):3-9. PubMed ID: 8431510
    [No Abstract]   [Full Text] [Related]  

  • 29. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
    Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
    Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in the development and manufacturing of antibody-drug conjugates.
    Ducry L
    Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting enzymes for cancer therapy: old enzymes in new roles.
    Deonarain MP; Epenetos AA
    Br J Cancer; 1994 Nov; 70(5):786-94. PubMed ID: 7947082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.
    HariKrishna D; Rao AR; Krishna DR
    Drug News Perspect; 2003 Jun; 16(5):309-18. PubMed ID: 12942162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developments with targeted enzymes in cancer therapy.
    Bagshawe KD; Sharma SK; Burke PJ; Melton RG; Knox RJ
    Curr Opin Immunol; 1999 Oct; 11(5):579-83. PubMed ID: 10508703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
    Eccles SA; Court WJ; Box GA; Dean CJ; Melton RG; Springer CJ
    Cancer Res; 1994 Oct; 54(19):5171-7. PubMed ID: 7923136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody directed enzymes revive anti-cancer prodrugs concept.
    Bagshawe KD
    Br J Cancer; 1987 Nov; 56(5):531-2. PubMed ID: 3426915
    [No Abstract]   [Full Text] [Related]  

  • 36. Prodrug-activating systems in suicide gene therapy.
    Springer CJ; Niculescu-Duvaz I
    J Clin Invest; 2000 May; 105(9):1161-7. PubMed ID: 10791987
    [No Abstract]   [Full Text] [Related]  

  • 37. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
    Yoon KJ; Potter PM; Danks MK
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.
    Both GW
    Curr Opin Mol Ther; 2009 Aug; 11(4):421-32. PubMed ID: 19649987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.
    Senter PD
    FASEB J; 1990 Feb; 4(2):188-93. PubMed ID: 2404820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.
    Fang L; Sun D
    Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.